Geron | GERN - Selling And Administration Expenses


Geron reported $35.42M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Amgen USD 1.58B 354M Mar/2026
Bio Techne USD 109.34M 4.35M Mar/2026
Cassava Sciences USD 6.66M 1.24M Dec/2025
Cytokinetics USD 104.9M 13.17M Mar/2026
Esperion Therapeutics USD 39.42M 456K Dec/2025
Exelixis USD 139.6M 16.58M Mar/2026
Genmab DKK 208M 60M Dec/2025
Geron USD 35.42M 6.24M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
Incyte USD 328.1M 62.31M Mar/2026
MacroGenics USD 7.94M 1.96M Dec/2025
Novartis USD 3.14B 296M Mar/2026
Novavax USD 25.53M 1.34M Dec/2025